Colombian Government Cuts Price of Novartis Cancer Drug

Colombia’s Ministry of Health and Social Protection unilaterally ruled to cut the price of Novartis’ leukemia treatment Gleevec by 44 percent, after negotiations with the Swiss drugmaker failed.

Novartis is now obligated to sell their drug at a reduced price. Gleevec is patented until the summer of 2018.